{"id":"NCT02641730","sponsor":"Janssen Pharmaceutical K.K.","briefTitle":"An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12-15","primaryCompletion":"2017-03-28","completion":"2018-07-17","firstPosted":"2015-12-29","resultsPosted":"2019-02-21","lastUpdate":"2025-02-04"},"enrollment":159,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Palmoplantar Pustulosis"],"interventions":[{"type":"DRUG","name":"Guselkumab","otherNames":["CNTO 1959"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"EXPERIMENTAL"},{"label":"Group 3","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of guselkumab for the treatment of participants with palmoplantar pustulosis.","primaryOutcome":{"measure":"Change From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score at Week 16","timeFrame":"Baseline and Week 16","effectByArm":[{"arm":"Placebo","deltaMin":-7.79,"sd":10.596},{"arm":"Guselkumab 100 mg","deltaMin":-15.08,"sd":11.252},{"arm":"Guselkumab 200 mg","deltaMin":-11.07,"sd":7.779}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"0.017"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":32,"countries":["Japan"]},"refs":{"pmids":["31268476"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":53},"commonTop":["Nasopharyngitis","Injection Site Erythema","Eczema","Dental Caries","Arthralgia"]}}